On September 15, 2021 ENcell, a contract development and production company specializing in cell therapy, reported on the 15th that it signed a contract manufacturing agreement (CMO) with Ingenium Therapeutics on the 8th for an incurable leukemia treatment (IGNK001) (Press release, Ingenium Therapeutics, SEP 15, 2021, View Source [SID1234643519]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this consignment production contract, ENcell will carry out turnkey production of 1/2 phase of samples and investigational drugs (IP) required for clinical trial approval (IND) of an anti-leukemia targeted NK cell therapy based on the Memory-like NK platform.

Jong-wook Jang, CEO of ENCell, said, "We will do our best to ensure that Ingenium Therapeutics’ NK cell therapy product successfully enters clinical trials," and added, "We will implement Ingenium Therapeutics’ latest technology with our GMP technology and know-how." "It will contribute to the development of advanced biopharmaceuticals," he said.